Dr. Wistinghausen Discusses Targeted Therapies for Pediatric NHL

Birte Wistinghausen, MD
Published: Thursday, May 31, 2018



Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma (NHL).

The Children’s Oncology Group is currently conducting trials with targeted therapies in the frontline setting. ANHL1131 is a phase II/III trial evaluating the safety and efficacy of rituximab (Rituxan) in children or adolescents with higher-risk NHL. These are patients with B-cell lymphoma or B-cell leukemia, says Wistinghausen.

There is also an open study evaluating chemotherapy in combination with brentuximab vedotin (Adcetris) or crizotinib (Xalkori) in patients with newly diagnosed stage III/IV anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an anti-CD30 antibody, and ALCL expresses CD30, says Wistinghausen. Crizotinib is an ALK inhibitor, and more than 95% of pediatric patients with ALCL are ALK-positive. The study, ANHL12P1, is currently recruiting for the crizotinib arm.


Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma (NHL).

The Children’s Oncology Group is currently conducting trials with targeted therapies in the frontline setting. ANHL1131 is a phase II/III trial evaluating the safety and efficacy of rituximab (Rituxan) in children or adolescents with higher-risk NHL. These are patients with B-cell lymphoma or B-cell leukemia, says Wistinghausen.

There is also an open study evaluating chemotherapy in combination with brentuximab vedotin (Adcetris) or crizotinib (Xalkori) in patients with newly diagnosed stage III/IV anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an anti-CD30 antibody, and ALCL expresses CD30, says Wistinghausen. Crizotinib is an ALK inhibitor, and more than 95% of pediatric patients with ALCL are ALK-positive. The study, ANHL12P1, is currently recruiting for the crizotinib arm.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x